Kathimerini Greece Newsroom
The third dose of their Covid-19 vaccine neutralizes the Omicron variant, Pfizer Inc. announced in a joint statement with BioNTech SE.
In their first official announcement about the effectiveness of their vaccine against the Omicron variant, BioNTech and Pfizer reported that although 2 doses of the drug may not be sufficient enough to protect against the Omicron variant, a third dose of the vaccine increased neutralizing antibodies by 25 times more.
The companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real-world effectiveness against Omicron globally.
The companies will continue to develop a variant-specific vaccine for Omicron and expect to have it available by March 2022.
